Form 8-K - Current report:
SEC Accession No. 0000950170-25-106243
Filing Date
2025-08-11
Accepted
2025-08-11 08:05:46
Documents
12
Period of Report
2025-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fdmt-20250811.htm   iXBRL 8-K 44784
2 EX-99.1 fdmt-ex99_1.htm EX-99.1 153897
3 GRAPHIC img216297824_0.jpg GRAPHIC 6182
  Complete submission text file 0000950170-25-106243.txt   324040

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fdmt-20250811.xsd EX-101.SCH 24937
14 EXTRACTED XBRL INSTANCE DOCUMENT fdmt-20250811_htm.xml XML 4712
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Filer) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39782 | Film No.: 251200270
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)